While dupilumab’s use has been extended to children under 12, benralizumab shows no benefit to patients with eosinophilic esophagitis (EoE). Credit: Cincinnati Children’s Despite high hopes, a drug that wipes out the namesake cell type associated with the disease eosinophilic esophagitis (EoE) doesn’t make patients feel better and doesn’t reverse tissue damage in their throats. Meanwhile, data show that a different drug that had previously been approved for use in adults and teens with EoE is also safe and effective for children under 12 who weigh at least 15 kg Read More